- 米国企業
- Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc.CTXR
時価総額
$9066.8万
PER
2011年 9月30日 | 2012年 9月30日 | 2013年 9月30日 | 2015年 9月30日 | 2016年 9月30日 | 2018年 9月30日 | 2019年 9月30日 | 2020年 9月30日 | 2021年 9月30日 | 2022年 9月30日 | |
Cash and cash equivalents | 212 | 135 | - | 676,137 | 294,351 | 9 | 8 | 14 | 70 | 42 |
Prepaid expenses | - | - | - | 60,000 | 598,484 | 57,732 | 48,111 | 122,237 | 3 | 3 |
Total Current Assets | 212 | 135 | - | 736,137 | 892,835 | 10 | 8 | 14 | 73 | 45 |
Property and equipment, net | - | - | - | - | 3,742 | 1,483 | 590 | 1,577 | 7,023 | 4,100 |
Operating lease right-of-use asset, net | - | - | - | - | - | - | - | 986,204 | 822,828 | 646,074 |
Deposits | - | - | - | - | 2,167 | 2,167 | 57,093 | 57,093 | 38,062 | 38,062 |
In-process research and development | - | - | - | - | - | 19 | 19 | 19 | 59 | 59 |
Goodwill | - | - | - | - | 2 | 2 | 2 | 9 | 9 | 9 |
Total Other Assets | - | - | - | 5,401 | 21 | 21 | 21 | 29 | 69 | 69 |
Total Assets | 212 | 135 | - | 741,538 | 22 | 31 | 29 | 44 | 142 | 114 |
Accounts payable | 906 | - | 11,474 | 559,150 | 909,156 | 2 | 3 | 2 | 1 | 1 |
Accrued expenses | 3,950 | 4,150 | - | 8,260 | 958,101 | 181,657 | 246,225 | 164,040 | 621,960 | 1 |
Accrued compensation | - | - | - | - | 903,250 | 1 | 1 | 2 | 2 | 2 |
Operating lease liability | - | - | - | - | - | - | - | 158,999 | 177,237 | 196,989 |
Total Current Liabilities | 24,053 | 45,982 | 14,694 | 1 | 5 | 3 | 5 | 4 | 4 | 5 |
Deferred tax liability | - | - | - | - | - | - | - | 5 | 5 | 6 |
Operating lease liability – non current | - | - | - | - | - | - | - | 855,471 | 678,234 | 481,245 |
Total Liabilities | - | - | - | - | - | - | - | 10 | 10 | 11 |
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding | - | - | - | - | - | - | - | - | - | - |
Common stock - $0.001 par value; 400,000,000 shares authorized; 146,211,130 and 145,979,429 shares issued and outstanding at September 30, 2022 and 2021, respectively | 18,000 | 18,000 | 18,000 | 34,118 | 73,138 | 16,199 | 28,930 | 55,577 | 145,979 | 146,211 |
Additional paid-in capital | - | - | 62,522 | 8 | 34 | 68 | 80 | 104 | 228 | 232 |
Accumulated deficit | - | - | - | -9,040,549 | -17,336,247 | -40,257,838 | -55,819,982 | -70,593,867 | -96,047,821 | -129,688,467 |
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity | -23,841 | -45,847 | -14,694 | -635,213 | 17 | 28 | 24 | 34 | 133 | 103 |
Non-controlling interest | - | - | - | - | - | - | - | - | 600,380 | 600,380 |
Total Equity | - | - | - | - | - | - | - | - | 133 | 103 |
Total Liabilities and Equity | 212 | 135 | - | 741,538 | 22 | 31 | 29 | 44 | 142 | 114 |